

Role of Dopamine D₄ Receptors in Motor Hyperactivity Induced by Neonatal 6-Hydroxydopamine Lesions in Rats

Kehong Zhang, M.D., Ph.D., Frank I. Tarazi, Ph.D., and Ross J. Baldessarini, M.D.

The role of dopamine D₄ receptors in behavioral hyperactivity was investigated by assessing D₄ receptor expression in brain regions and behavioral effects of D₄ receptor-selective ligands in juvenile rats with neonatal 6-hydroxydopamine lesions, a laboratory model for attention deficit-hyperactivity disorder (ADHD). Autoradiographic analysis indicated that motor hyperactivity in lesioned rats was closely correlated with increases in D₄ but not D₂ receptor levels in caudate-putamen.

D₄-selective antagonist CP-293,019 dose-dependently reversed lesion-induced hyperactivity, and D₄-agonist CP-226,269 increased it. These results indicate a physiological role of dopamine D₄ receptors in motor behavior, and may suggest much-needed innovative treatments for ADHD.

[Neuropsychopharmacology 25:624–632, 2001]

© 2001 American College of Neuropsychopharmacology.
Published by Elsevier Science Inc.

KEY WORDS: Attention deficit-hyperactivity disorder; Autoradiography; Dopamine; D₄; 6-hydroxydopamine; Motor activity

Dopamine (DA) modulates physiological processes through activation of five G-protein coupled receptors of the D₁-like (D₁ and D₅) and D₂-like (D₂, D₃, and D₄) receptor families (Neve and Neve 1997). Since the cloning of their cDNA (Van Tol et al. 1991), D₄ receptors have received much attention, in part because some atypical antipsychotics, notably clozapine, bind to D₄ receptors with somewhat higher affinity than to the more prevalent D₂ receptors (Van Tol et al. 1991; Seeman et al. 1997; Tarazi et al. 1997; Tarazi and Baldessarini 1999).

Human D₄ receptors occur in multiple forms with 2–11 copies of a 16-amino acid (48 base-pair) sequence in the putative third intracellular loop of the peptide (Van Tol et al. 1992; Lichter et al. 1993; Asghari et al. 1994). Several recent genetic studies indicate that the 7-repeat D₄ receptor allele (D_{4.7}), a relatively uncommon variant, is more prevalent in patients with attention deficit-hyperactivity disorder (ADHD) (La Hoste et al. 1996; Bailey et al. 1997; Rowe et al. 1998; Faraone et al. 1999). Haplotype relative-risk analysis to assess allele transmission also suggests that the D_{4.7} receptor may be associated with ADHD (Swanson et al. 1998). The same D_{4.7} phenotype is also linked to personality traits related to ADHD, notably, novelty-seeking and impulsivity (Benjamin et al. 1996; Ebstein et al. 1996; Comings et al. 1999). Biochemical analysis of these D₄ receptor variants indicates that D_{4.7} receptors are less efficient in transducing extracellular DA signals to intracellular adenylyl cyclase than other forms with fewer repeat sequences (Asghari et al. 1995).

ADHD is a neuropsychiatric syndrome frequently found in school-aged children, especially boys, that is characterized by excesses of hyperactive, inattentive, and impulsive behavior (Barkley 1990). Salient features

From the Mailman Research Center, McLean Division of Massachusetts General Hospital, 115 Mill Street, Belmont, MA 02478, USA; and Consolidated Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA 02115 USA.

Address correspondence to: Kehong Zhang, M.D., Ph.D., Mailman Research Center, McLean Hospital, 115 Mill Street, Belmont, MA 02478, Tel.: 617-855-3222; Fax: 617-855-3479, E-mail: kz@mclean.harvard.edu

Received November 14, 2000; revised March 28, 2001; accepted April 9, 2001.

Online publication: 4/10/01 at www.acnp.org/citations/Npp041001102.

of ADHD are commonly modeled in juvenile rats following neonatal lesioning with 6-hydroxydopamine (6-OHDA) which destroys DA projections to forebrain (Shaywitz et al. 1976). Such rats exhibit several characteristics resembling core symptoms of ADHD, most notably, motor hyperactivity that occurs selectively during the periadolescent period, gradually declines as lesioned rats mature, and seems to represent deficient adaptation to environmental stimuli (Erinoff et al. 1979). The motor hyperactivity in this model can be dose-dependently antagonized by psychostimulants that are commonly used to alleviate symptoms of ADHD (Heffner and Seiden 1982; Luthman et al. 1989). Hyperactivity and attentional deficits that occur in ADHD are also modeled with genetic knockout mice that lack functional DA transporters (DAT) (Giros et al. 1996; Gainedtinov et al. 1999). However, the pathophysiology of these models may be dissimilar, and may or may not reflect mechanisms underlying clinical ADHD. Notably, the 6-OHDA lesioning model involves neonatal removal of DA with overgrowth of serotonin projections to forebrain (Kostrzewa et al. 1998), whereas the DAT knockout mouse involves a loss of the major mechanism for inactivating DA (Gainedtinov et al. 1999)—a mechanism that may be overexpressed in clinical ADHD (Dougherty et al. 1999; Dresel et al. 2000).

Association of D₄ receptor polymorphism with ADHD led us to study the expression of D₄ receptors in juvenile rats following neonatal 6-OHDA lesions using quantitative autoradiography. DA D₁-like and D₂-like receptor binding was examined for comparison. Effects of highly D₄-selective agents on hyperactivity were studied and compared to representative stimulants used to treat ADHD.

MATERIALS AND METHODS

Radioligands and Chemicals

[³H]Nemonapride (R[+]-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 85.5 Ci/mmol) and [³H]SCH-23390 (R[+]-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol; 81.4 Ci/mmol) were obtained from New England Nuclear (NEN; Boston, MA). [³H]β-CIT ([-]-2-β-carbomethoxy-3-β-[4-iodophenyl]-tropane; 64.7Ci/mmol) was obtained from Tocris Cookson (Bristol, UK). Tritium-sensitive Hyperfilm and autoradiography standards were from Amersham (Arlington Heights, IL). D-19 developer and fixative were from Eastman-Kodak (Rochester, NY). (+)-Amphetamine sulfate, 1,3-ditolyguanidine (DTG), *cis*-flupenthixol dihydrochloride, 6-OHDA hydrobromide, ketanserin tartrate, S(-)-pindolol, and S(-)-sulpiride were from Sigma—Research Biochemicals International (RBI; Natick, MA). (+)-Methylphenidate

hydrochloride was provided by Celgene (Warren, NJ). CP-226,269 and CP-293,019 were generously donated by Pfizer (Groton, CT). All other drugs and chemicals were purchased from Fisher Scientific (Dallas, TX) or Sigma Chemicals (St. Louis, MO).

Neonatal Lesioning

Sprague-Dawley rats (Charles River Labs., Wilmington, MA) were maintained under a 12-h artificial daylight/dark schedule (on, 7 A.M.-7 P.M.), with free access to tap-water and standard rat chow. On postnatal day (PD) 1, male pups were assigned to lactating dam (10/each). On PD 5, pups received a subcutaneous injection of desipramine hydrochloride (25 mg/kg). 45 Minutes later, pups randomly received an intracisternal injection of vehicle (0.9% NaCl containing 0.1% ascorbic acid), or 6-OHDA hydrobromide (100 μg free base) under hypothermal anesthesia (Shaywitz et al. 1976). Pups were returned to nursing dams immediately after the intracranial injections. A total of 210 rat pups were included in the study. All procedures were approved by the McLean Hospital Institutional Animal Care and Use Committee, in compliance with applicable federal and local guidelines for experimental use of animals. The extent of lesioning was verified by quantifying DAT binding with [³H]β-CIT (Kula et al. 1999) at the completion of behavioral experiments.

Behavioral Experiments

Motor activity was monitored individually for 90 min in the periadolescent period between PD 21 and 30, using an infrared photobeam activity monitoring system (San Diego Instruments, San Diego, CA) connected with a microcomputer. Behavioral testings were conducted in a novel environment (17×8×8 inch transparent plastic cages with 4×8 horizontal infrared beams), usually between 10:00 and 16:00 h in the absence of food and water, except for experiments involving nocturnal testing (at 22:00–04:00 h). Locomotor activity was defined as breaking of consecutive photobeams, and accumulated every 5 min.

Test agents were dissolved in 0.9% saline or 35% 2-hydroxypropyl-β-cyclodextrin, and given intraperitoneally (i.p.) immediately prior to testing. Each subject was evaluated in two behavioral testing sessions (one with vehicle, the other with a test drug), separated by at least three days, and in randomized order. Some rats given CP-293,019 were pretreated with methysergide (2 mg/kg, i.p.) 30 min before behavioral testing.

Receptor Autoradiography

Rats were sacrificed 48 h after the last behavioral testing session (on PD 32) by rapid decapitation, and brains

were quickly removed and frozen. Coronal brain sections (10 μm) were prepared in a cryostat at -17°C , thaw-mounted on gelatin-coated microscopic slides and stored at -80°C until quantitative autoradiographic assays.

Densities of D_2 -like and D_4 receptors were determined autoradiographically as previously detailed and characterized pharmacologically (Tarazi et al. 1997, 1998a,b). Briefly, tissue sections were preincubated for 60 min at room temp in 50 mM Tris-HCl buffer containing (mM): NaCl (120), KCl (5), CaCl_2 (2), and MgCl_2 (1). Sections were then transferred to fresh buffer containing 1 nM [^3H]nemonapride in the presence of 0.5 μM 1,3-ditolyguanidine and 0.1 μM pindolol to block σ and 5-HT $_{1A}$ sites for D_2 -like receptor assays. The D_2/D_3 -selective antagonist raclopride (300 nM) was included in D_4 assays to fully occlude D_2 and D_3 sites. Nonspecific binding was determined in both assays with 10 μM S(-)-sulpiride. D_1 -like receptors were assayed with 1.0 nM [^3H]SCH-23390 in the presence of 40 nM ketanserin to mask 5-HT $_{2A/2C}$ receptor sites, with nonspecific binding determined with 1 μM *cis*-flupenthixol (Tarazi et al. 1998a).

After incubation with a radioligand, brain sections were washed twice (5 min in ice-cold buffer), rinsed in deionized water and air-dried. Sections were exposed to tritium-sensitive Hyperfilm for 2–6 weeks before standard photographic processing. Radioligand binding was quantified with a computerized image analyzer (Image Research Inc., St. Catharines, Ontario), and converted to nCi/mg tissue using [^3H]reference standards, with specific binding expressed in fmol/mg tissue, as detailed previously (Tarazi et al. 1997, 1998a,b).

Data Analysis

Lesion effects on receptor density were initially analyzed by two-way analysis of variance (ANOVA; for overall effects of treatment by brain region), followed by *post-hoc* Dunnett's *t*-tests for planned comparisons. Two-tailed probability of $<.05$ indicated statistically significant differences. Behavioral effects of test agents were analyzed similarly. Relationships between lesion-induced motor hyperactivity and DA receptor changes were evaluated by Spearman Rank Correlation (r_s).

RESULTS

Lesion-induced Motor Hyperactivity and Effects of Psychostimulants

Behavioral effects of neonatal lesions were examined by monitoring motor activity between PD 21–30 in a novel environment, to provoke exploratory activity. Lesioned rats exhibited overall much greater and more prolonged spontaneous motor activity than sham-lesioned littermate controls during both daytime and

nocturnal testing (Figure 1, Panels A and B). Notably, motor activity of lesioned rats did not differ significantly from controls for the first 5–10 min of testing session, but failed to decline throughout the 90 min session, long after arousal in control rats had greatly diminished. Hyperactivity in lesioned rats was reduced by both (+)-amphetamine and (+)-methylphenidate (Figure 1, Panel C). In contrast to their motor-inhibiting effects in lesioned rats, both psychostimulants greatly stimulated motor activity in sham-lesioned controls, as expected (Figure 1, Panel D).

Effects of Lesions on DA Transporters and Receptors

Rats were sacrificed 2 days after the last behavioral testing for autoradiographic analysis of DA transporters and receptors. Neonatal 6-OHDA lesions reduced DAT binding in caudate-putamen (CPu) by $>80\%$ (39.3 ± 3.5 vs. 218 ± 9.2 fmol/mg in lesioned vs. sham-control rats). The lesions significantly increased D_4 receptor binding in CPu (lateral: 40.3%; medial: 35.2%), but not in nucleus accumbens (NAc) or prefrontal cortex (PFC) (Table 1). D_2 -like ($D_2/D_3/D_4$) receptor binding also was increased in CPu, and not in NAc and PFC by the lesions. The magnitude of increase of D_2 -like receptors (16.6% and 18.3% in lateral and medial CPu, respectively) was about half of that of D_4 receptors. D_1 -like receptor binding was unchanged in CPu, NAc and PFC by neonatal 6-OHDA lesions. Lesion-induced motor hyperactivity was strongly correlated with increases of D_4 receptor binding in CPu in individual rats (Figure 2; Spearman nonparametric $r_s = 0.657$, $p < .05$), but not with increases of D_2 -like receptors.

Behavioral Effects of D_4 Receptor-selective Ligands

The highly D_4 -selective antagonist CP-293,019 dose-dependently antagonized lesion-induced hyperactivity (Figure 3, Panel A). At a dose of 10 mg/kg (i.p.), motor activity in lesioned rats was inhibited by approximately 40%, and at 30 mg/kg, it was indistinguishable from sham-lesioned controls. Nocturnal hyperactivity (equivalent to daytime activity in humans) in lesioned rats also was completely reversed by CP-293,019 at 30 mg/kg (Figure 3, Panel B). In striking contrast to the effects of the D_4 antagonist CP-293,019, a highly D_4 -selective agonist, CP-226,269, produced a dose-dependent exacerbation of lesion-induced hyperactivity (Figure 3, Panel C). However, neither D_4 -agent affected motor activity in sham-lesioned controls (Figure 3, Panel D).

Pretreatment of 6-OHDA-lesioned rats with methysergide, a broad-spectrum 5-HT receptor antagonist, did not affect their motor responses to subsequent injection of CP-293,019 (Figure 4). Methysergide treatment alone did not alter motor activity. Eticlopride, a D_2 receptor antagonist, inhibited locomotor activity in sham-




Figure 1. Hyperactivity induced by neonatal 6-OHDA lesions, and effects of psychostimulant drugs. **Panel A:** Daytime activity, 10 A.M.–4 P.M. (n = 23/group); **Panel B:** Nocturnal activity, 10 P.M.–4 A.M. (n = 17); **Panel C:** Effects of psychostimulants in 6-OHDA-lesioned rats, 10 A.M.–4 P.M. (n = 14–23); **Panel D:** Effects of psychostimulants in sham-lesioned rats, 10 A.M.–4 P.M. (n = 12).

lesioned controls, but not in 6-OHDA-lesioned rats at a moderate dose of 0.5 mg/kg (Figure 5).

DISCUSSION

In accord with previous studies (Shaywitz et al. 1976; Heffner and Seiden 1982; Luthman et al. 1989), neonatal 6-OHDA lesions resulted in spontaneous motor hyperactivity when rats were tested at a later, periadolescent, developmental stage in a novel environment. Also consistent with previous findings (Heffner and Seiden 1982; Luthman et al. 1989), lesion-induced hyperactiv-

ity was antagonized by both amphetamine and methylphenidate (Figure 1). Neonatal 6-OHDA lesions significantly increased D₄ receptor levels selectively in CPu. D₂-like receptor binding in the same brain region was also increased, but to a lesser extent. Motor hyperactivity induced by the lesions was significantly correlated with increased D₄ receptor levels but not D₂ levels (Figure 2).

Previous studies of postnatal development of DA receptors in rat brain indicated that D₄ receptors undergo extensive pruning at 4–5 weeks after birth (Tarazi et al. 1998b). The finding that D₄ receptor binding in CPu was significantly increased in lesioned rats above levels

Table 1. Effects of Neonatal 6-OHDA Lesions on Dopamine Receptor Binding in Rat Forebrain. Data are Specific Binding, As Mean fmol/mg Tissue ± SEM. By ANOVA: (*) *p* < 0.05, (**) *p* < 0.01, Significantly Different (Boldface) From Sham-Lesioned Control Littermates (N = 12)

	D ₁ -like		D ₂ -like		D ₄	
	Sham	6-OHDA	Sham	6-OHDA	Sham	6-OHDA
CPu/Lateral	253.6 ± 13.7	228.5 ± 11.6	194.3 ± 9.8	226.5 ± 7.2*	20.6 ± 2.2	28.9 ± 1.4**
CPu/Medial	244.1 ± 14.3	233.4 ± 11.8	133.3 ± 6.8	157.7 ± 6.0*	14.2 ± 1.5	19.2 ± 1.7**
NAc	167.9 ± 10.4	173.9 ± 9.7	114.6 ± 8.2	102.2 ± 6.5	14.0 ± 1.2	15.0 ± 1.6
PFC	36.3 ± 2.4	39.0 ± 2.3	9.8 ± 0.4	10.3 ± 0.5	2.0 ± 0.4	2.0 ± 0.2

Brain regions are caudate-putamen (CPu), nucleus accumbens septi (NAc), and prefrontal cerebral cortex (PFC).




Figure 2. Relationship between motor hyperactivity and changes of dopamine receptor binding in CPu of 6-OHDA-lesioned rats ($n = 12$), analyzed by Spearman Rank Correlation (r_s).

in controls (Table 1) at a comparable age (PD 32) suggests that this pruning process may be hampered by neonatal 6-OHDA lesions. In addition, the severity of lesion-induced hyperactivity was highly correlated with the extent of the apparent up-regulation of D_4 , but not

D_2 receptors (Figure 2), further implicating impaired development of D_4 receptors in abnormal behaviors induced by the lesions.

The role of up-regulated D_4 receptors in motor hyperactivity was further investigated by assessing the behavioral effects of a D_4 -selective antagonist and agonist (Sanner et al. 1998; Zorn et al. 1997). The D_4 antagonist CP-293,019 dose-dependently reversed lesion-induced motor hyperactivity without affecting activity in control littermates that received sham lesions (Figure 3). The D_4 agonist CP-226,269, in contrast, dose-dependently exacerbated motor hyperactivity in lesioned rats without affecting motor activity in unlesioned control rats. The finding that lesion-induced motor hyperactivity can be dose-dependently reversed by a D_4 antagonist rather than agonist suggests that stimulant properties in normal animals or agonistic properties at DA receptors are poor indicators for behavioral effects in ADHD models. These observations also indicate that psychostimulants do not antagonize motor hyperactivity by stimulating D_4 receptors.

In addition to blocking or reversing neuronal transport of DA, stimulant drugs also release serotonin (5-hydroxytryptamine, 5-HT) (Ritz et al. 1990). Increased innervation of forebrain structures, especially neostriatum, by serotonergic neurons is well documented in




Figure 3. Effects of D_4 receptor-selective agents on hyperactivity induced by neonatal 6-OHDA lesions. **Panel A:** Effects of CP-293,019 in 6-OHDA-lesioned rats, 10 A.M.–4 P.M. ($n = 23$ /group); **Panel B:** Effects of CP-293,019 in 6-OHDA-lesioned rats, 10 P.M.–4 A.M. ($n = 13$); **Panel C:** Effects of CP-226,269 in 6-OHDA-lesioned rats, 10 A.M.–4 P.M. ($n = 17$); **Panel D:** Effects of CP-293,019 and CP-226,269 in sham-lesioned rats, 10 A.M.–4 P.M. ($n = 10$).




Figure 4. Effects of methysergide pretreatment on motor-inhibiting effects of CP-293,019 in 6-OHDA-lesioned rats (n = 14/group). Methysergide (2 mg/kg, i.p.) was administered 30 min prior to testing.

rats following neonatal lesioning with 6-OHDA (Kostrzewa et al. 1998). In hyperactive juvenile rats with neonatal 6-OHDA lesions, as well as hyperactive DAT knockout mice, the motor-inhibiting effects of stimulants seem to be mediated by enhanced release of 5-HT (Heffner and Seiden 1982; Gainedtinov et al. 1999). Therefore, we tested the possibility of interaction of D₄ antagonist CP-293,019 with 5-HT neurotransmission with methysergide, a broad-spectrum 5-HT receptor antagonist. Pretreatment of 6-OHDA-lesioned rats with methysergide did not affect their motor responses to subsequent injection of CP-293,019 (Figure 4), suggesting that the behavioral effects of the D₄ antagonist were not mediated by increased release of 5-HT. Methysergide alone failed to affect lesion-induced hyperactivity, further indicating that the motor-inhibiting effects of CP-293,019 in lesioned rats were not related to its moderate potency at 5-HT_{1A} and 5-HT_{2A} receptors (K_i = 150

and 500 nM, respectively; Sanner et al. 1998). Instead, these findings indicate that CP-293,019 antagonized lesion-induced hyperactivity by a mechanism distinct from that of stimulants.

A contribution of D₂ receptor blockade to behavioral effects of CP-293,019 seems very unlikely since this agent interacts very weakly at D₂ receptors (K_i >3.0 μM; Sanner et al. 1998). In addition, our recent studies indicated that CP-293,019 did not alter rotational behavior induced by D₂ receptor agonists in adult rats with unilateral nigrostriatal DA lesions (Zhang et al. 2001). To further rule out involvement of D₂ receptors, behavioral effects of eticlopride were investigated. At a moderate dose (0.5 mg/kg, i.p.), eticlopride markedly inhibited motor activity in sham-lesioned controls, but did not alter such behavior in 6-OHDA-lesioned rats (Figure 5). These observations accord with previous findings that adult rats with neonatal 6-OHDA lesions were less sensitive to D₂ receptor antagonists, in association with increased D₂ receptor binding (Bruno et al. 1985). Although eticlopride blocks D₂ receptors with only limited selectivity (D₂ vs. D₄ K_i-ratio ≥20; Van Tol et al. 1991), the finding that it did not affect motor hyperactivity in lesioned rats at a dose that was effectively motor-inhibitory and produced some catalepsy in intact rats indicates that the effect of CP-293,019 is unlikely to be mediated by D₂ receptors.

Dysfunction of the frontal cerebral cortex is critically involved in the pathophysiology of ADHD (Barkley 1997; Faraone and Biederman 1998). Inhibition of behavioral responses, a primary function of the PFC in humans, has been found consistently to be deficient in patients with ADHD, based on neuropsychological testing (Barkley et al. 1992). Abnormal PFC structure or function is also strongly suggested by brain imaging studies using various techniques (Ernst and Zametkin 1995). The PFC sends glutamatergic projections to many subcortical structures, including CPu, NAc, and midbrain areas (Fonnum et al. 1981; Walaas 1981). Removal of these excitatory corticofugal efferents by PFC




Figure 5. Effects of eticlopride (0.5 mg/kg, i.p.) on locomotor activity (n = 12/group) in: Panel A: 6-OHDA-lesioned rats; Panel B: sham-lesioned rats; inset: cumulative score for the entire session in sham controls.

ablation results in hyperactivity in response to environmental stimuli in primates (Fuster 1989; Wilkinson et al. 1997), as well as supersensitive behavioral responses to both external and internal stimuli in rats (Bubser and Schmidt 1990; Flores et al. 1996; Lacroix et al. 1998). Relatively high levels of D₄ receptors are expressed in glutamatergic pyramidal neurons and GABAergic interneurons in PFC, as well as in the nerve terminals of glutamatergic projections from PFC to CPu (Ariano et al. 1997; Mrzljak et al. 1996; Tarazi et al. 1998a; De la Garza and Madras 2000), suggesting that the excitatory output from PFC to subcortical structures may be inhibited by D₄ receptors. We did not find altered D₄ receptor binding in PFC or NAc of 6-OHDA-lesioned rats (Table 1). However, a substantial increase in D₄ binding was detected in CPu, and this increase correlated closely with motor hyperactivity (Figure 2). Up-regulated, and possibly supersensitive, D₄ receptors may contribute to hyperactivity in lesioned rats by selectively inhibiting excitatory output from PFC to CPu. Further studies on *in vivo* regulation of glutamate release by D₄ receptors in normal and lesioned subjects are required to test this hypothesis.

Finally, the treatment of ADHD has for many years been based on the ability of stimulant drugs to attenuate hyperactivity and improve cognition (Barkley 1990; Swanson 1993; Goldman et al. 1998). These drugs, however, are far from satisfactory, owing to their short-lived benefits, tendency to impair appetite and sleep and to induce abnormal movements, as well as their potential for abuse or illicit distribution (Goldman et al. 1998). The effectiveness of CP-293,019 in antagonizing motor hyperactivity induced by neonatal DA lesions encourages clinical testing of innovative treatments of ADHD with D₄ receptor selective agents.

REFERENCES

- Ariano MA, Wang J, Noblett KL, Larson ER, Sibley DR (1997): Cellular distribution of the rat D₄ dopamine receptor protein in the CNS using anti-receptor antisera. *Brain Res* 752:26–34
- Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HHM (1995): Modulation of intracellular cyclic AMP levels by different human dopamine D₄ receptor variants. *J Biochem* 65:1157–1165
- Asghari V, Schoots O, Van Kats S, Ohara K, Jovanovic V, Guan H-G, Bunzow JR, Petronis A, Van Tol HHM (1994): Dopamine D₄ receptor repeat: Analysis of different native and mutant forms of the human and rat genes. *Mol Pharmacol* 46:364–373
- Bailey HN, Palmer CG, Ramsey C, Cantwell D, Kim K, Woodward JA, McGough J, Asarnow RF, Nelson S, Smalley SL (1997): DRD4 gene and susceptibility to attention deficit hyperactivity disorder. *Am J Med Genet Neuropsychiat Genet* 74:623–624
- Barkley RA (1990): Attention Deficit Hyperactivity Disorder: A Handbook For Diagnosis And Treatment. New York, Guilford Press
- Barkley RA (1997): Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. *Psychol Bull* 121:65–94
- Barkley RA, Grodzinsky G, DuPaul GJ (1992): Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report. *J Abnorm Child Psychol* 20:163–188
- Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH (1996): Population and familial association between D₄ dopamine receptor gene and measures of novelty-seeking. *Nature Genetics* 12:81–84
- Bruno JP, Stricker EM, Zigmond MJ (1985): Rats given dopamine-depleting brain lesions as neonates are subsensitive to dopamine antagonists as adults. *Behav Neurosci* 99:771–775
- Bubser M, Schmidt WJ (1990): 6-Hydroxydopamine lesion of the rat prefrontal cortex increase locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. *Behav Brain Res* 37:157–168
- Comings DE, Gonzalez N, Wu S, Gade R, Muhleman D, Saucier G, Johnson P, Verde R, Rosenthal RJ, Lesieur HR, Ruge LJ, Miller WB, MacMurray JP (1999): Studies of the 48 bp polymorphism of the DRD4 gene in impulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. *Am J Med Genet* 88:358–368
- De la Garza II R, Madras BK (2000): [³H]PNU-101958, a D₄ dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain. *Synapse* 37:232–244
- Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fishman AJ (1999): Dopamine transporter density in patients with attention deficit hyperactivity disorder. *Lancet* 354:2132–2133
- Dresel S, Krause J, Krause KH, La Fougere C, Brinkbaumer K, Kung HF, Hahn K, Tatsch K (2000): Attention deficit hyperactivity disorder: binding of [^{99m}Tc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. *Eur J Nucl Med* 27:1518–1524
- Ebstein RP, Novik O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH (1996): Dopamine D₄ receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. *Nature Genetics* 12:78–80
- Erinoff L, MacPhail RC, Heller A, Seiden LS (1979): Age-dependent effects of 6-hydroxydopamine on locomotor activity in the rat. *Brain Res* 164:195–205
- Ernst M, Zametkin A (1995): The interface of genetics, neuroimaging, and neurochemistry in attention-deficit hyperactivity disorder. In Bloom FE, Kupfer DJ (eds), *Psychopharmacology: The Fourth Generation Of Progress*. New York, Raven Press, pp. 1643–1652
- Faraone SV, Biederman J (1998): Neurobiology of attention-deficit hyperactivity disorder. *Biol Psychiatry* 59:628–637
- Faraone SV, Biederman J, Weiffenbach B, Keith T, Chu MP, Weaver A, Spencer TJ, Wilens TE, Frazier J, Cleves M, Sakai J (1999): Dopamine D₄ gene 7-repeat allele and

- attention deficit hyperactivity disorder. *Am J Psychiatry* 156:768–770
- Flores G, Wood GK, Liang JJ, Quirion R, Srivastava LK (1996): Enhanced amphetamine sensitivity and increased dopamine D₂ receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. *J Neurosci* 16:7366–7375
- Fonnum F, Storm-Mathisen J, Divac I (1981): Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibers in rat brain. *Neuroscience* 6:863–873
- Fuster JM (1989): In *The Prefrontal Cortex*. New York, Raven Press, pp. 51–82
- Gainedtinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999): Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. *Science* 283:397–401
- Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996): Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature* 379:606–612
- Goldman LS, Genel M, Bezman RJ, Slanetz PJ (1998): Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *JAMA* 279:1100–1107
- Heffner TG, Seiden LS (1982): Possible involvement of serotonergic neurons in the reduction of locomotor hyperactivity caused by amphetamine in neonatal rats depleted of brain dopamine. *Brain Res* 244:81–90
- Kostrzewa RM, Reader TA, Descarries L (1998): Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. *J Neurochem* 70:889–898
- Kula NS, Baldessarini RJ, Tarazi FI, Fisser R, Wang S, Trometer J, Neumeyer JL (1999): [³H]β-CIT: a radioligand for dopamine transporter in rat brain tissue. *Eur J Pharmacol* 385:291–294
- La Hoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, Kennedy JL (1996): Dopamine D₄ receptor gene polymorphism is associated with attention deficit hyperactivity disorder. *Mol Psychiatry* 1:128–131
- Lacroix L, Broersen LM, Weiner I, Feldon J (1998): The effects of excitotoxic lesion of the medial prefrontal cortex on latent inhibition, prepulse inhibition, food hoarding, elevated plus maze, activity avoidance and locomotor activity in the rat. *Neuroscience* 82:431–442
- Lichter JB, Barr CL, Kennedy JL, Van Tol HHM, Kidd KK, Livak KJ (1993): A hypervariable segment in the human dopamine receptor D₄ (DRD4) gene. *Hum Mol Genet* 6:767–773
- Luthman J, Fredriksson A, Lewander T, Jonsson G, Archer T (1989): Effects of amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. *Psychopharmacology* 99:550–557
- Mrzljak L, Bergson C, Pappy M, Huff R, Levenson R, Goldman-Rakic PS (1996): Localization of dopamine D₄ receptors in GABAergic neurons of the primate brain. *Nature* 381:245–248
- Neve KA, Neve RL (1997): Molecular biology of dopamine receptors. In Neve KA, Neve RL (eds), *The Dopamine Receptors*. Totowa, New Jersey, Humana Press, pp. 27–76
- Ritz MC, Cone EJ, Kuhar MJ (1990): Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. *Life Sci* 46:635–645
- Rowe DC, Stever C, Giedinghagen LN, Gard JM, Cleveland HH, Terris ST, Mohr JH, Sherman S, Abramowitz A, Waldman ID (1998): Dopamine DRD4 receptor polymorphism and attention-deficit hyperactivity disorder. *Mol Psychiatry* 3:419–426
- Sanner MA, Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci WS, Collins JL, Duignan DB, Di Prete CC, Lee JS, Trozzi A (1998): Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D₄ receptor antagonist. *Bioorg Med Chem Lett* 8:725–730
- Seeman P, Corbett R, Van Tol HHM (1997): Atypical neuroleptics have low affinity for dopamine D₂ receptors or are selective for D₄ receptors. *Neuropsychopharmacology* 16:93–110
- Shaywitz RA, Yager RD, Klopfer JH (1976): Selective brain dopamine depletion in developing rats: An experimental model of minimal brain dysfunction. *Science* 191:305–308
- Swanson JM (1993): Effect of stimulant medication on children with attention deficit disorder: a “review of review”. *Exceptional Child* 60:154–162
- Swanson JM, Sunahara GA, Kennedy JL, Regino R, Fineberg E, Wigal T, Lerner M, Williams L, La Hoste GJ, Wigal S (1998): Association of the dopamine receptor D₄ (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD). *Mol Psychiatry* 3:38–41
- Tarazi FI, Baldessarini RJ (1999): Dopamine D₄ receptors: significance for molecular psychiatry at the millennium. *Mol Psychiatry* 4:529–538
- Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ (1998a): Localization of dopamine receptor subtypes in caudate-putamen and nucleus accumbens septi of rat brain: Comparison of D₁-, D₂-, and D₄-like receptors. *Neuroscience* 83:169–76
- Tarazi FI, Tomasini EC, Baldessarini RJ (1998b): Postnatal development of D₄-like receptors in rat forebrain: Comparison with D₂-like receptors. *Dev Brain Res* 110:227–33
- Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL (1997): Long-term effects of S(+)-N-n-propyl-norapomorphine compared with typical and atypical antipsychotics: Differential increases of cerebrocortical D₂-like and striatolimbic D₄-like dopamine receptors. *Neuropsychopharmacology* 17:186–96
- Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning of a human dopamine D₄ receptor gene with high affinity for the antipsychotic clozapine. *Nature* 350:614–619
- Van Tol HHM, Wu CM, Guan H-C, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992): Multiple dopamine D₄ receptor variants in the human population. *Nature* 358:149–152
- Walaas I (1981): Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. *Neuroscience* 6:399–405
- Wilkinson LS, Dias R, Thomas KL, Augood SJ, Everitt BJ,

Robbins TW, Roberts AC (1997): Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioral response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. *Neuroscience* 80:717–730

Zhang K, Tarazi FI, Baldessarini RJ (2001): Nigrostriatal

dopaminergic denervation enhances dopamine D₄ receptor binding in rat caudate-putamen. *Pharmacol Biochem Behav*, in press

Zorn SH, Jackson ER, Johnson CG, Lewis JM, Fliri A (1997): CP-226,269 is a selective dopamine D₄ receptor agonist. *Soc Neurosci Abstr* 23:685